NASDAQ, EXAS - Exact Sciences Cor
EXACT Sciences Corporation is an applied genomics company that develops
proprietary DNA-based technologies for use in the detection of cancer. We have
selected colorectal cancer as the first application of our technologies. We have
licensed certain of our technologies, on an exclusive basis through December
2010, to Laboratory Corporation of America? Holdings ("LabCorp?") in connection
with a commercial testing service that is marketed in the United States under
the name "PreGen-Plus?." PreGen-Plus, which is based on our Version 1
technology, is LabCorp's non-invasive stool-based DNA testing service for the
detection of colorectal cancer in the average-risk population. Royalties from
LabCorp's sales of PreGen-Plus, and other license fees from LabCorp, represent
our primary source of revenue.
Colorectal cancer is the second leading cause of cancer death in the U.S.
and the leading cause of cancer death among non-smokers. ...
Read SEC Filing on NASDAQ.com »